No Relationship Between Drug Transporter Genetic Variants and Tenofovir Plasma Concentrations or Changes in Glomerular Filtration Rate in HIV-infected Adults

Overview

Journal J Acquir Immune Defic Syndr

Specialty Infectious Diseases

Date 2015 Jan 7

PMID 25559596

Citations 5

Authors

Wasna Sirirungsi

Saik Urien

Linda Harrison

Jiraporn Kamkon

Yardpiroon Tawon

Nuananong Luekamlung

Suchart Thongpaen

Ampaipith Nilmanat

Gonzague Jourdain

Marc Lallemant

Sophie Le Coeur

Nicole Ngo-Giang-Huong

Andrew Owen

Tim R Cressey

Affiliations

Soon will be listed here.

Citing Articles

Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy.

Bukkems V, Smolders E, Jourdain G, Burger D, Colbers A, Cressey T J Clin Pharmacol. 2020; 61(3):388-393.

PMID: 32960984 PMC: 7891399. DOI: 10.1002/jcph.1746.

Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate.

Cressey T, Siriprakaisil O, Kubiak R, Klinbuayaem V, Sukrakanchana P, Quame-Amaglo J Int J Infect Dis. 2020; 97:365-370.

PMID: 32553717 PMC: 7392195. DOI: 10.1016/j.ijid.2020.06.037.

Tenofovir Exposure during Pregnancy and Postpartum in Women Receiving Tenofovir Disoproxil Fumarate for the Prevention of Mother-to-Child Transmission of Hepatitis B Virus.

Cressey T, Harrison L, Achalapong J, Kanjanavikai P, Patamasingh Na Ayudhaya O, Liampongsabuddhi P Antimicrob Agents Chemother. 2018; 62(12).

PMID: 30275094 PMC: 6256809. DOI: 10.1128/AAC.01686-18.

Drug Transporter Genetic Variants Are Not Associated with TDF-Related Renal Dysfunction in Patients with HIV-1 Infection: A Pharmacogenetic Study.

Nishijima T, Hayashida T, Kurosawa T, Tanaka N, Oka S, Gatanaga H PLoS One. 2015; 10(11):e0141931.

PMID: 26535588 PMC: 4633171. DOI: 10.1371/journal.pone.0141931.

Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment.

Cressey T, Avihingsanon A, Halue G, Leenasirimakul P, Sukrakanchana P, Tawon Y Clin Infect Dis. 2015; 61(4):633-9.

PMID: 25921689 PMC: 4607735. DOI: 10.1093/cid/civ346.

References

Droste J, Wissen C, Kearney B, Buffels R, Vanhorssen P, Hekster Y . Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers. Antimicrob Agents Chemother. 2005; 49(2):680-4. PMC: 547290. DOI: 10.1128/AAC.49.2.680-684.2005. View

Lavielle M, Mentre F . Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software. J Pharmacokinet Pharmacodyn. 2007; 34(2):229-49. PMC: 1974848. DOI: 10.1007/s10928-006-9043-z. View

Kiser J, Carten M, Aquilante C, Anderson P, Wolfe P, King T . The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther. 2007; 83(2):265-72. DOI: 10.1038/sj.clpt.6100269. View

Rodriguez-Novoa S, Labarga P, Soriano V, Egan D, Albalater M, Morello J . Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis. 2009; 48(11):e108-16. DOI: 10.1086/598507. View

Rodriguez-Novoa S, Labarga P, Soriano V . Pharmacogenetics of tenofovir treatment. Pharmacogenomics. 2009; 10(10):1675-85. DOI: 10.2217/pgs.09.115. View

Chaisiri K, Bowonwatanuwong C, Kasettratat N, Kiertiburanakul S . Incidence and risk factors for tenofovir-associated renal function decline among Thai HIV-infected patients with low-body weight. Curr HIV Res. 2010; 8(7):504-9. DOI: 10.2174/157016210793499259. View

Nishijima T, Komatsu H, Gatanaga H, Aoki T, Watanabe K, Kinai E . Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. PLoS One. 2011; 6(7):e22661. PMC: 3143186. DOI: 10.1371/journal.pone.0022661. View

Benaboud S, Hirt D, Launay O, Pannier E, Firtion G, Rey E . Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women. Antimicrob Agents Chemother. 2011; 56(2):857-62. PMC: 3264275. DOI: 10.1128/AAC.05244-11. View

Poizot-Martin I, Solas C, Allemand J, Obry-Roguet V, Pradel V, Bregigeon S . Renal impairment in patients receiving a tenofovir-cART regimen: impact of tenofovir trough concentration. J Acquir Immune Defic Syndr. 2012; 62(4):375-80. DOI: 10.1097/QAI.0b013e31827ce4ee. View

10.

Yombi J, Pozniak A, Boffito M, Jones R, Khoo S, Levy J . Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity. AIDS. 2014; 28(5):621-32. DOI: 10.1097/QAD.0000000000000103. View

11.

Manosuthi W, Sukasem C, Thongyen S, Nilkamhang S, Sungkanuparph S . ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen. J Antimicrob Chemother. 2014; 69(8):2195-201. DOI: 10.1093/jac/dku129. View